Prevention of hyperphosphatemia in kidney disorder patients

  • US 5,597,815 A
  • Filed: 07/13/1995
  • Issued: 01/28/1997
  • Est. Priority Date: 07/13/1995
  • Status: Expired due to Term
  • ×
    • Pin Icon | RPX Insight
    • Pin
First Claim
Patent Images

1. A method of treating a patient having renal osteodystrophy while avoiding hyperphosphatemia comprising administering to said patient a vitamin D compound that has minimal effect on blood serum phosphorus of said patient, said vitamin D compound selected from a 19-nor-vitamin D2 compound having the formula:

  • ##STR5## where X1 and X2 each represent, independently, hydrogen or a hydroxy-protecting group; and

    where R1 is selected from hydrogen, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5 -- alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent; and

    where each of R2, R3, and R.sup. 4, independently, is selected from hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent; and

    where R1 and R2, taken together represent an oxo group, or an alkylidene group, ═

    CR2 R3, or the group --(CH2)p --, where p is an integer from 2 to 5; and

    where R3 and R4, taken together, present an oxo group, or a group --(CH2)q --, where q is an integer from 2 to 5; and

    where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl.

View all claims
  • 4 Assignments
    ×
    ×

    Thank you for your feedback

    ×
    ×